132 related articles for article (PubMed ID: 23393915)
21. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
Thomas AA; Rini BI; Lane BR; Garcia J; Dreicer R; Klein EA; Novick AC; Campbell SC
J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579
[TBL] [Abstract][Full Text] [Related]
22. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib efficacy against advanced renal cell carcinoma.
Motzer RJ; Michaelson MD; Rosenberg J; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Wilding G
J Urol; 2007 Nov; 178(5):1883-7. PubMed ID: 17868732
[TBL] [Abstract][Full Text] [Related]
24. Sequential sorafenib and sunitinib for renal cell carcinoma.
Sablin MP; Negrier S; Ravaud A; Oudard S; Balleyguier C; Gautier J; Celier C; Medioni J; Escudier B
J Urol; 2009 Jul; 182(1):29-34; discussion 34. PubMed ID: 19447417
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
26. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Yildiz I; Sen F; Basaran M; Ekenel M; Agaoglu F; Darendeliler E; Tunc HM; Ozcan F; Bavbek S
Jpn J Clin Oncol; 2011 Dec; 41(12):1380-7. PubMed ID: 22013228
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
[TBL] [Abstract][Full Text] [Related]
28. [A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].
Cui C; Li S; Chi Z; Si L; Sheng X; Mao L; Lian B; Wang X; Tang B; Guo J
Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):375-8. PubMed ID: 26463030
[TBL] [Abstract][Full Text] [Related]
29. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
Kahl C; Hilgendorf I; Freund M; Casper J
Onkologie; 2008 Sep; 31(8-9):485. PubMed ID: 18787358
[No Abstract] [Full Text] [Related]
30. A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.
Ornstein MC; Wood LS; Elson P; Allman KD; Beach J; Martin A; Zanick BR; Grivas P; Gilligan T; Garcia JA; Rini BI
J Clin Oncol; 2017 Jun; 35(16):1764-1769. PubMed ID: 28113029
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Olsen MR; Hudes GR; Burke JM; Edenfield WJ; Wilding G; Agarwal N; Thompson JA; Cella D; Bello A; Korytowsky B; Yuan J; Valota O; Martell B; Hariharan S; Figlin RA
J Clin Oncol; 2012 Apr; 30(12):1371-7. PubMed ID: 22430274
[TBL] [Abstract][Full Text] [Related]
32. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.
Lee JL; Kim MK; Park I; Ahn JH; Lee DH; Ryoo HM; Song C; Hong B; Hong JH; Ahn H
Ann Oncol; 2015 Nov; 26(11):2300-5. PubMed ID: 26347107
[TBL] [Abstract][Full Text] [Related]
33. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
Bjarnason GA; Khalil B; Hudson JM; Williams R; Milot LM; Atri M; Kiss A; Burns PN
Urol Oncol; 2014 May; 32(4):480-7. PubMed ID: 24321258
[TBL] [Abstract][Full Text] [Related]
34. Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices.
Schnadig ID; Hutson TE; Chung H; Dhanda R; Halm M; Forsyth M; Vogelzang NJ
Clin Genitourin Cancer; 2014 Dec; 12(6):413-21. PubMed ID: 25163396
[TBL] [Abstract][Full Text] [Related]
35. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
Harshman L; Srinivas S
Onkologie; 2008 Sep; 31(8-9):432-3. PubMed ID: 18787349
[No Abstract] [Full Text] [Related]
36. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
[TBL] [Abstract][Full Text] [Related]
37. Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib.
Teo YL; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
Target Oncol; 2015 Sep; 10(3):429-37. PubMed ID: 25502986
[TBL] [Abstract][Full Text] [Related]
38. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers.
He Z; Guo G; Zhang C; Li X; Fu W; Jin J; Zhang X; Zhou L
Chin Med J (Engl); 2014; 127(8):1450-3. PubMed ID: 24762587
[TBL] [Abstract][Full Text] [Related]
40. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
